Ligand Pharma (LGND) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ligand Pharma (LGND) PT Raised to $237 at H.C. Wainwright
February 7, 2020 8:29 AM ESTH.C. Wainwright analyst Joseph Pantginis raised the price target on Ligand Pharma (NASDAQ: LGND) to $237.00 (from $214.00) while maintaining a Buy rating.
The analyst commented, "Yesterday, Ligand announced 4Q19 and 2019 financial results, posting GAAP EPS of ($0.43) and $33.13 per share, respectively, compared with our... More
